HomeSearch for 'First'

First - News and Articles about commonly prescribed drugs

Verastem doses first affected person in Section I/II scientific trial of duvelisib together with venetoclax

Posted in News on 8th September 2018

Verastem, Inc., working as Verastem Oncology, a biopharmaceutical firm targeted on creating and commercializing medicines to enhance the survival and high quality of lifetime of most cancers sufferers, at the moment introduced dosing of the primary affected person in a multicenter Section I/II scientific trial on the Dana-Farber/Harvard Most cancers Middle of duvelisib together with venetoclax in sufferers with relapsed or refractory continual lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

“Duvelisib and venetoclax goal completely different pathways basic to CLL biology and have distinct mechanisms of motion. We’ve got discovered that CLL cells from duvelisib-treated sufferers are primed for apoptosis in response to remedy with brokers reminiscent of venetoclax. We now have the chance to discover whether or not this mixture could also be an efficient remedy for the remedy of sufferers with CLL,” mentioned Matthew Davids, MD, MMSc, Assistant Professor of Drugs, Harvard Medical Faculty, and Affiliate Director, Middle for Power Lymphocytic Leukemia, Dana-Farber Most cancers Institute and the research’s principal investigator. “We’re excited to conduct this trial, as these new, focused brokers in growth have the potential to enhance sufferers’ response by mixture therapies.”

This trial will examine venetoclax, an oral, potent, selective inhibitor of BCL-2 – a key mediator of the intrinsic pathway of apoptosis, the method of programmed cell loss of life – given together with duvelisib. Preclinical information assist this mixture, as duvelisib has been proven to upregulate BCL-2 transcript and protein expression ranges and improve the power of venetoclax to induce apoptosis in ex vivo human CLL cells. The trial will use BH3 profiling – a practical assay that determines the apoptotic threshold of a cell – which Davids and colleagues beforehand used to indicate that inhibition of phosphoinositide Three-kinase (PI3K) enhances the apoptotic threshold of CLL cells and sensitivity to BCL-2 inhibition.

The part I major goals are to find out the utmost tolerated dose, in addition to the really helpful part II dose of venetoclax for this mixture routine with duvelisib in sufferers with relapsed or refractory CLL/SLL. The part II major goal is to find out the speed of full response (CR) of the mix, as outlined by the Worldwide Workshop on Power Lymphocytic Leukemia (IWCLL) 2008 standards.

“As we proceed to discover the potential of duvelisib, we’re very inspired by the sturdy scientific rationale and the preclinical information supporting the mix of duvelisib and venetoclax. We anticipate this trial will assist improve our understanding of the consequences of this mixture within the remedy of sufferers with CLL/SLL,” mentioned Diep Le, MD, PhD, Chief Medical Officer of Verastem Oncology. “Our purpose at Verastem Oncology is to carry progressive therapeutic choices to sufferers residing with cancers which might be in want of further remedy choices. Given the numerous unmet want that exists amongst sufferers residing with CLL and SLL, we stay up for the perception generated from this trial that might inform potential future scientific growth for duvelisib.”

Supply:

http://investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2366298

First Generic Model of EpiPen Will get FDA Approval

Posted in News on 17th August 2018

August 16, 2018

Epinephrine auto-injectors are used in the emergency treatment of allergic reactions

Epinephrine auto-injectors are used within the emergency therapy of allergic reactions

The Meals and Drug Administration (FDA) has permitted the primary generic model of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency therapy of allergic reactions (Kind I) together with anaphylaxis. Teva Prescribed drugs will market the generic epinephrine auto-injectors in zero.15mg and zero.3mg strengths.

Just lately, Mylan, the producer of EpiPen, launched an announcement reporting continued provide points as a result of interruptions in manufacturing of their epinephrine auto-injectors. In December of 2016, Mylan launched an “licensed generic” model of EpiPen, however because the product is manufactured utilizing the identical formulation, course of, and services because the model, it’s topic to the identical delays; licensed generics are made underneath a model’s current new drug software.

“Immediately’s approval of the primary generic model of the most-widely prescribed epinephrine auto-injector within the US is a part of our longstanding dedication to advance entry to decrease value, secure and efficient generic options as soon as patents and different exclusivities now not stop approval,” mentioned FDA Commissioner Scott Gottlieb, MD. “This approval means sufferers residing with extreme allergy symptoms who require fixed entry to life-saving epinephrine ought to have a lower-cost choice, in addition to one other permitted product to assist defend in opposition to potential drug shortages.”

Associated Articles

Not like different generic approvals, epinephrine auto-injectors are thought-about “mixture merchandise” as a result of they encompass each a drug and a tool, making the approval course of tougher. “These merchandise may be laborious to repeat, and subsequently typically do not face well timed generic competitors as soon as patents and exclusivities are now not a block to approval,” mentioned Gottlieb, including that the Company is constantly engaged on methods to assist information producers by means of the method to assist the event of generic variations of those complicated merchandise.

In a press assertion, Teva introduced that “the corporate is making use of its full assets to this vital launch within the coming months and is raring to start supplying the market.”

For extra info go to FDA.gov.

Scroll all the way down to see the following article

First Marijuana-Based mostly Drug Accepted to Deal with LGS, Dravet Syndrome

Posted in News on 26th June 2018

June 25, 2018

Epidiolex is the first Rx formulation of a highly-purified, plant derived cannabidiol

Epidiolex is the primary Rx formulation of a highly-purified, plant derived cannabidiol

The Meals and Drug Administration (FDA) has authorized Epidiolex (cannabidiol oral answer; GW Prescription drugs) for the therapy of seizures related to Lennox-Gastaut syndrome and Dravet syndrome in sufferers ≥2 years of age. This marks the primary authorized drug that comprises an energetic ingredient derived from marijuana in addition to the primary therapy authorized for sufferers with Dravet syndrome.

The approval of Epidiolex was primarily based on information from three randomized, double-blind, placebo-controlled trials (N=516) involving sufferers with both Lennox-Gastaut (Examine 1 and a couple of) or Dravet syndrome (Examine three). The first efficacy measure in Examine 1 and a couple of was the p.c change from baseline within the frequency (per 28 days) of drop seizures over the 14-week therapy interval. When taken with different drugs, therapy with Epidiolex 20mg/kg/day resulted in a considerably better median discount within the frequency of drop seizures vs placebo (Examine 1: -44% vs -22% [P=.01]; Examine 2: -42% vs -17% [P<.01 for each]). In Examine three, the median discount within the frequency of convulsive seizures was considerably better within the Epidiolex 20mg/kg/day group vs placebo (-39% vs -13%; P<.01). For all research, a discount in seizures was seen inside four weeks of therapy initiation and the impact remained typically constant over the 14-week therapy interval. 

Associated Articles

Sleepiness, sedation, lethargy, elevated liver enzymes, decreased urge for food, diarrhea, rash, fatigue, malaise, weak point, insomnia, sleep problem, poor high quality sleep, and infections have been among the many most typical antagonistic results seen with Epidiolex therapy. Essentially the most severe dangers embody suicidal ideation and makes an attempt, agitation, new or worsening despair, aggression, and panic assaults. 

Epidiolex is at present categorised as a Schedule I substance as a result of it’s a chemical element of the hashish plant. Earlier than it turns into out there to sufferers, the therapy will should be rescheduled; GW Prescription drugs expects this to happen inside the subsequent 90 days.

Epidiolex can be provided as a 100mg/mL strawberry-flavored oral answer in 100mL bottles and is anticipated to be out there for applicable sufferers in Fall 2018.

For extra info name (833) 424-6724 or go to GWPharm.com.

Scroll all the way down to see the following article

AAA doses first sufferers in two medical research with PSMA-R2 for prostate most cancers

Posted in News on 23rd June 2018

Superior Accelerator Functions S.A. (AAA), a Novartis firm and chief in nuclear medication theragnostics, immediately introduced that the primary sufferers have been dosed in two Part I/II medical research of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Particular Membrane Antigen (PSMA), which is usually expressed on prostate most cancers cells.

The PROter examine is an open-label, multi-center, dose-escalation/dose-expansion trial evaluating therapy with 177Lu-PSMA-R2 RadioLigand Remedy in sufferers with PSMA optimistic progressive, metastatic castration-resistant prostate most cancers following earlier systemic therapy. Major targets for Part I embrace characterizing the drug’s security profile and tolerability, as properly figuring out a really useful Part II dose. The first goal for Part II is evaluation of antitumor exercise, as measured by radiographic progression-free survival. Different targets embrace prostate-specific antigen (PSA) response, time to PSA development and general survival. Roughly 96 sufferers are anticipated to be enrolled within the PROter trial.

The PROfind examine is an open-label, multi-center trial evaluating Positron Emission Tomography (PET) imaging with 68Ga-PSMA-R2 in sufferers with biochemical relapse and metastatic prostate most cancers. The first goal of the examine is to evaluate the protection and tolerability of a single administration of 68Ga-PSMA-R2. Secondary targets embrace analysis of pharmacokinetics, biodistribution and dosimetry of 68Ga-PSMA-R2, in addition to comparability with typical imaging modalities. Roughly 30 sufferers are anticipated to be enrolled within the PROfind trial.

“Advancing PSMA-R2 into medical research is a significant milestone for AAA,” commented Germo Gericke, M.D., Head of Analysis and Improvement at Superior Accelerator Functions. “That is the second theragnostic program in our oncology pipeline and we’re wanting to discover the complete potential of this progressive platform in massive affected person populations, akin to prostate most cancers.”

Prostate most cancers is the second commonest kind of most cancers in males worldwide resulting in substantial morbidity and mortality. It represents the second commonest reason behind most cancers dying in males within the USA and the third commonest reason behind dying in developed nations. Most circumstances of prostate most cancers are curable if recognized at an early stage. Nonetheless, as much as 40% of the sufferers with prostate most cancers develop biochemical relapse inside 10 years after preliminary native therapy with healing intentfour and a few sufferers will progress to metastatic prostate most cancers. Regardless of the effectiveness of hormone remedy within the therapy of metastatic prostate most cancers, sufferers who reside lengthy sufficient will in the end succumb to metastatic castration-resistant prostate most cancers.

Supply:

The First Glyphosate Most cancers Lawsuit Trial Begins This Week

Posted in News on 19th June 2018

46-year-old DeWayne Johnson of Bernicia, California is a husband and father of three kids. He labored for the native college district as a groundskeeper for 3 years between 2012 and 2015. At this time, he suffers from terminal non-Hodgkin’s lymphoma, a deadly type of most cancers.

Physicians say he has lower than a 12 months to stay. Johnson attributes his illness to publicity to glyphosate, the lively ingredient within the herbicide Roundup. This week, he can have a chance to carry producer Monsanto accountable, as his case towards the agribusiness big turns into the primary to go to trial.

For many years, Monsanto – which can quickly be assimilated into international pharmaceutical conglomerate Bayer AG – has allegedly hid details about the carcinogenicity of glyphosate. Final month, Decide Curtis Karnow of the San Francisco Superior Courtroom, who might be presiding over Johnson’s case, issued an order that can enable the jury to contemplate these allegations along with the medical proof connecting the plaintiff’s illness to the product.

Within the order, Decide Karnow wrote,

Inner correspondence famous by Johnson may help a jury discovering that Monsanto has lengthy been conscious of the danger that its glyphosate-based herbicides are carcinogenic…however has constantly sought to affect the scientific literature to stop its inner issues from reaching the general public sphere and to bolster its defenses in merchandise legal responsibility actions.”

Decide Karnow’s order opens the door for the jury to contemplate punitive damages along with compensatory damages.

Though Johnson’s will not be an official “bellwether case,” attorneys for Monsanto in addition to these representing roughly four,000 different plaintiffs suing the agribusiness big are watching intently. Relying on the end result, it may imply a few years of authorized battles and big claims, for which Monsanto’s new proprietor at Bayer AG might be accountable. Alternatively, a discovering for the defendant may spell bother for plaintiffs who’ve been injured by glyphosate.

Monsanto continues to assert that glyphosate poses no hazard to human well being, citing a questionable EPA “draft threat evaluation report” refuting a 2015 assertion from the World Well being Group concluding that glyphosate is prone to be carcinogenic. Literature nonetheless obtainable on the firm’s web site asserts that “Glyphosate-based herbicides are supported by one of the crucial in depth worldwide human well being and environmental results databases ever compiled for a pesticide product,” claiming that “complete toxicological and environmental destiny research carried out over the past 40 years have repeatedly demonstrated the robust security profile of this broadly used herbicide.”

Attorneys for Monsanto additionally plan to introduce proof they declare exhibits Johnson’s most cancers was attributable to different elements and can try to refute present scientific proof of the well being risks related to glyphosate.